

FORM PTO-1449  
(Rev. 2-32)U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

MBHB00-327-A

Serial No.

09/835,603

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)



Applicant:

Sarah S. Bacus et al.

Filing Date:

04/16/2001

Group:

1632

TECH CENTER 1600/2900  
NOV 07 2002

## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
KCS	1.	2001/044124	11/22/2001	Bacus			
KCS	2.	2002/037541	3/28/2002	Obata			

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
KCS	3.	WO 01/79557	10/25/2001	PCT			<input checked="" type="checkbox"/>	<input type="checkbox"/>
KCS	4.	WO 01/79855	10/25/2001	PCT			<input checked="" type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

KCS	5.	Arteaga et al., "p185 <sup>c-erbB-2</sup> Signaling Enhances Cisplatin-induced Cytotoxicity in Human Breast Carcinoma Cells: Association between an Oncogenic Receptor Tyrosine Kinase and Drug-Induced DNA Repair," Cancer Res., 54:3758-3765, 1994.
KCS	6.	Bacus et al., "AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival," Oncogene, England, Vol. 21, No.22:3532-3540, May 16, 2002.
KCS	7.	Bacus et al., "Akt2 upregulation in HER-2/neu-overexpressing breast cancers: Implications to their clinical and biological behavior," Proceedings of the American Association For Cancer Research Annual, Vol. 42:243, March 2001.
KCS	8.	Bacus et al., "Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells," Oncogene, 12:2535-2547, 1996.


EXAMINER

KCS

DATE CONSIDERED

9/20/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.



RECEIVED  
NOV 07 2002

Sheet 2 of 2

TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

✓	9.	Bacus et al., "Potential Use of Image Analysis for the Evaluation of Cellular Predicting Factors for Therapeutic Response in Breast Cancers," Anal. Quant. Cytol. Histol., 19:316-328, 1997.
✓	10.	Bacus et al., "Type 1 Receptor Tyrosine Kinases Are Differentially Phosphorylated in Mammary Carcinoma and Differentially Associated with Steroid Receptors," American Journal of Pathology, 148(2):549-558, 1996.
✓	11.	Cantley and Neel, "New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway," Proc. Natl. Acad. Sci. U.S.A., 96:4240-45, 1999.
✓	12.	Cobleigh et al., "Mutational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease," J. Clin. Oncol., 17:2639-2648, 1999.
✓	13.	Datta et al., "Cellular survival: a play in three Akts," Genes and Dev., 13:2905-27, 1999.
✓	14.	Hancock et al., "A Monoclonal Antidoby against the c-erbB-2 Protein Enhances the Cytotoxicity of cis-Diamminedichloroplatinum against Human Breast and Ovarian Tumor Cell Lines," Cancer Res., 51:4575-4580, 1991.
✓	15.	Li et al., "PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer," Science 275:1943-47, 1997.
✓	16.	Liaw et al., "Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome," Nat. Genet., 16:64-67, 1997.
✓	17.	Liu et al., "Heregulin Regulation of Akt/Protein Kinase B in Breast Cancer Cells," Biochem. Biophys. Res. Commun., 261:897-903, 1999.
✓	18.	National Institue of Health Consensus Development Conference: Steroid Receptors in Breast Cancer, 1979, Bethesda, MD.
✓	19.	Nelen et al., "Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease," Hum. Mol. Genet., 6:1383-87, 1997.
✓	20.	Peles et al., "Cell-type specific Interaction of Neu differentiation factor (NDF/hergulin) with Neu/HER-2 suggests complex ligand - receptor relationships," EMBO J., 12(3):961-971, 1993.
✓	21.	Peles et al., "Neu and its Ligands: From an Oncogene to Neural Factors," BioEssays, 15(12):815-924, 1993.
✓	22.	Pettmann and Henderson, "Neuronal Cell Death," Neuron, 20:633-47, 1998.
✓	23.	Shak, "Overview of the Trastuzumab (Herceptin) Anti-HER2 Monoclonal Antibody Clinical Program in HER2-Overexpressing Metastatic Breast Cancer," Semin. Oncol., 26:71-77, 1999.
✓	24.	Sliwkowski et al., "Nonclinical Studies Addressing the Mechanism of Action of Trastuzumab (Herceptin)," Semin. Oncol., 26:60-70, 1999.
✓	25.	Yang et al., "Bad, a Heterodimeric Partner for Bcl-x <sub>L</sub> and Bcl-2, Displaces Bax and Promotes Cell Death," Cell, 80:285-91, 1995.
✓	26.	Zundel and Giaccia, "Inhibition of the anti-apoptotic PI(3)K/Akt/Bad pathway by stress," Genes Dev., 12:941-46, 1998.
✓	27.	Daly et al., "Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells," Cancer Res., 57(17):3804-11, 1997.

EXAMINER

DATE CONSIDERED

9/25/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.